0000000001305105
AUTHOR
Artis Galvanovskis
Lung on a Chip Development from Off-Stoichiometry Thiol–Ene Polymer
Institute of Solid-State Physics, University of Latvia as the Center of Excellence has received funding from the European Union’s Horizon 2020 Framework Programme H2020-WIDESPREAD-01-2016-2017-TeamingPhase2 under grant agreement No. 739508, project CAMART2. Finally, we would like to thank Biol. Kaspars Tars from Latvian Biomedical research and study center for giving us the opportunity to participate in this consortium and contribute to Latvian scientists’ effort in response to the COVID-19 pandemic.
Development of lung on a chip model for SARS-CoV-2 research
Kopš 2019. gada beigām pasauli plosa SARS-CoV-2 izraisītā COVID-19 pandēmija. Lai gan COVID-19 vakcīnas ir tikušas izstrādātas rekordlielā ātrumā, pandēmija ir akcentējusi nepieciešamību padziļināti pētīt koronavīrusus, kā arī sagatavoties nākotnes respiratorām infekcijām. Lai nodrošinātu ātru atbildi pret jaunām respiratorām infekcijām, ir jāpilnveido in vitro modeļi, kas ļautu ātrāk pārprofilēt esošās zāles un izstrādāt jaunas priekš šīm infekcijām. Ņemot vērā orgānu uz čipa sistēmu pielietošanu dažādu slimību pētniecībā, šajā bakalaura darbā tika izveidota plaušas uz čipa sistēma. Tajā tika optimizēta funkcionalizēšana, plūsma un šūnu uzsēšana. Tā tika raksturota ar imūnfluorescenci un 3…
Early and strong antibody responses to SARS-CoV-2 predict disease severity in COVID-19 patients
Abstract Background Antibody response to SARS-CoV-2 is a valuable biomarker for the assessment of the spread of the virus in a population and evaluation of the vaccine candidates. Recent data suggest that antibody levels also may have a prognostic significance in COVID-19. Most of the serological studies so far rely on testing antibodies against spike (S) or nucleocapsid (N) protein, however antibodies can be directed against other structural and nonstructural proteins of the virus, whereas their frequency, biological and clinical significance is unknown. Methods A novel antigen array comprising 30 SARS-CoV-2 antigens or their fragments was developed and used to examine IgG, IgA, IgE and Ig…
Additional file 1 of Early and strong antibody responses to SARS-CoV-2 predict disease severity in COVID-19 patients
Additional file 1: Table S1. Predicted SARS-CoV-2 epitopes expressed in-house. Table S2. Commercial SARS-CoV-2 proteins and human control proteins.
Additional file 2 of Early and strong antibody responses to SARS-CoV-2 predict disease severity in COVID-19 patients
Additional file 2: Fig. S1. Performance of the SARS-CoV-2 antigen array. a A representative image of testing anti-SARS-CoV-2 IgG antibodies in serum from a COVID-19 patient. b Dynamic range of the IgG assay. The antigen array was tested with serial dilutions of a serum sample from a COVID-19 patient. Each dilution was tested in duplicates.